These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 6703151)

  • 21. Venlafaxine withdrawal symptoms.
    Benazzi F
    Can J Psychiatry; 1996 Sep; 41(7):487. PubMed ID: 8884044
    [No Abstract]   [Full Text] [Related]  

  • 22. Clonidine in the treatment of Tourette's syndrome exacerbation due to haloperidol withdrawal.
    Max JE; Rasmussen SA
    J Nerv Ment Dis; 1986 Apr; 174(4):243-6. PubMed ID: 3457098
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recurrent neuroleptic malignant syndrome due to haloperidol and amantadine.
    Hermesh H; Sirota P; Eviatar J
    Biol Psychiatry; 1989 Apr; 25(7):962-5. PubMed ID: 2720007
    [No Abstract]   [Full Text] [Related]  

  • 24. Spontaneous activity and apomorphine stereotypy during and after withdrawal from 3 1/2 months continuous administration of haloperidol: some methodological issues.
    Waddington JL; Gamble SJ
    Psychopharmacology (Berl); 1980; 71(1):75-7. PubMed ID: 6779327
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacotherapy of Tourette's syndrome and associated disorders.
    Cohen DJ; Riddle MA; Leckman JF
    Psychiatr Clin North Am; 1992 Mar; 15(1):109-29. PubMed ID: 1549543
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fatal hyperthermia following haloperidol therapy of sedative-hypnotic withdrawal.
    Greenblatt DJ; Gross PL; Harris J; Shader RI; Ciraulo DA
    J Clin Psychiatry; 1978 Aug; 39(8):673-5. PubMed ID: 681307
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Differentiation of stereotypies from neuroleptic-related dyskinesias in autistic children.
    Meiselas KD; Spencer EK; Oberfield R; Peselow ED; Angrist B; Campbell M
    J Clin Psychopharmacol; 1989 Jun; 9(3):207-9. PubMed ID: 2500463
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Differences between haloperidol- and pimozide-induced withdrawal syndrome: a role for Ca2+ channels.
    Antkiewicz-Michaluk L; Karolewicz B; Michaluk J; Vetulani J
    Eur J Pharmacol; 1995 Dec; 294(2-3):459-67. PubMed ID: 8750706
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tourette syndrome, pimozide, and school phobia: the neuroleptic separation anxiety syndrome.
    Linet LS
    Am J Psychiatry; 1985 May; 142(5):613-5. PubMed ID: 3857012
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clomipramine efficacy for tics, obsessions, and compulsions in Tourette's syndrome and obsessive-compulsive disorder: a case study.
    Ratzoni G; Hermesh H; Brandt N; Lauffer M; Munitz H
    Biol Psychiatry; 1990 Jan; 27(1):95-8. PubMed ID: 2297555
    [No Abstract]   [Full Text] [Related]  

  • 31. Neuroleptic withdrawal.
    Maisami M; Golant D
    J Am Acad Child Adolesc Psychiatry; 1991 Mar; 30(2):336. PubMed ID: 1673122
    [No Abstract]   [Full Text] [Related]  

  • 32. Comparison of withdrawal of typical and atypical antipsychotic drugs: a case study.
    Alphs LD; Lee HS
    J Clin Psychiatry; 1991 Aug; 52(8):346-8. PubMed ID: 1869497
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Study of bipathic effect of haloperidol.
    Voronina TA; Belopolskaya MV; Kheyfets IA; Dugina JL; Sergeeva SA; Epstein OI
    Bull Exp Biol Med; 2008 May; 145(5):620-2. PubMed ID: 19145297
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Vesta variant of Tourette's disease: treatment with haloperidol.
    Still CN; Ham CH
    South Med J; 1973 Nov; 66(11):1222-5. PubMed ID: 4147666
    [No Abstract]   [Full Text] [Related]  

  • 35. [Acute recurrent dystonia secondary to neuroleptic suppression].
    Modrego Pardo P; Pérez Trullen JM
    Rev Clin Esp; 1997 Mar; 197(3):211-2. PubMed ID: 9273591
    [No Abstract]   [Full Text] [Related]  

  • 36. Cholinergic rebounds and withdrawal syndromes.
    Pary RJ; Klontz W; Foxworth JM
    Am J Psychiatry; 1980 Feb; 137(2):261. PubMed ID: 7352599
    [No Abstract]   [Full Text] [Related]  

  • 37. Effects of chronic naloxone administration on vacuous chewing movements and catalepsy in rats treated with long-term haloperidol decanoate.
    Egan MF; Ferguson JN; Hyde TM
    Brain Res Bull; 1995; 38(4):355-63. PubMed ID: 8535858
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sleep in schizophrenic patients on and off haloperidol therapy. Clinically stable vs relapsed patients.
    Neylan TC; van Kammen DP; Kelley ME; Peters JL
    Arch Gen Psychiatry; 1992 Aug; 49(8):643-9. PubMed ID: 1637254
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cholinergic rebound in neuroleptic withdrawal syndromes.
    Lieberman J
    J Clin Psychiatry; 1981 Apr; 42(4):179. PubMed ID: 6110656
    [No Abstract]   [Full Text] [Related]  

  • 40. Effects of apomorphine administration on rearing activity of control and experimental rats withdrawn from long-term haloperidol treatment.
    Bernardi MM; Palermo-Neto J
    Gen Pharmacol; 1984; 15(4):363-5. PubMed ID: 6541605
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.